Skip to content

Warenkorb

Der Warenkorb ist leer.

Gesamt (exkl. MwSt.) £0,00
Warenkorb überprüfen & bezahlen
Antikörper

Anti-ERBB2 / HER2 / CD340 Reference Antibody (pertuzumab)

Produktgrößen
100 ug
£385,00
CHA054-100UG
1 mg
£965,00
CHA054-1MG
Über dieses Produkt
SKU:
CHA054
Zusätzliche Namen:
ErbB-2, ERBB2, CD340, p185, proto-oncogene Neu, herstatin|pertuzumab
Anwendung:
Cell-based/Functional Assay, Detection/Quantitation, ELISA, FACS, Flow Cytometry
Buffer:
25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2
Klonalität:
Recombinant Monoclonal
Konzentration:
1 mg/ml
Weitere Details:
Anti-ERBB2 / HER2 / CD340 Reference Antibody (pertuzumab)(CHA054) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 143.9 kDa.
Immunogen:
ERBB2 / HER2 / CD340
Isotyp:
IgG1
Physischer Zustand:
Lyophilized
Reinheit:
>95%
Reaktivitäten:
Human, Mouse, Cynomolgus
Sequenz:
EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Versandbedingungen:
Blue Ice
Spezifität:
ERBB2 / HER2 / CD340
Lagerbedingungen:
2-8[o]C, -70[o]C Avoid freeze/thaw cycles.
Hersteller:
Sanyou Biopharmaceuticals
Typ:
Antibody: Biosimilar Antibody
  • Datenblatt des Herstellers:CHA054
Anti- Human HER2 ( Pertuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of anti- Human HER2 ( Pertuzumab) is 99.02%, determined by SEC-HPLC.
Immobilized human HER2 (His Tag, 2ug/mL) can bind to anti- Human HER2 (Pertuzumab) with an EC50 of 0.01375 ug/mL.
BT474 cells were stained with anti- Human HER2 ( Pertuzumab) , with isotype and secondary-only controls. Flow analysis showed specific binding of the antibody, with an EC50 of 0.2994 ug/mL
The combination of two anti-human HER2 monoclonal antibodies, pertuzumab and trastuzumab, was evaluated for in vivo anti-tumor activity against NCI-N87 xenografts in Balb/c nude mice. Results demonstrated significant tumor growth inhibition: at a dose of 5 mg/kg, the tumor growth inhibition (TGI) rate reached 73.8% on day 37.